NCT07448402Not yet recruiting
Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
National Registry of Patients With Psoriatic Disease Receiving Interleukin-23 Inhibitor Therapy Within the Costa Rican Social Security System
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are: * Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice? * What is the safety profile and treatment persistence of IL-23 inhibitors in this population? * Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA/BASDAI) and adverse-event reporting through a national registry.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 26 Feb 2026
- Start date
- 1 May 2026
- Primary completion date
- 31 May 2031
- Lead sponsor
- Caja Costarricense de Seguro Social
- Diseases
- Psoriasis
- NCT number
- NCT07448402
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 May 2026 to the primary completion date, 31 May 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None specified (all patients meeting inclusion criteria are eligible).
Who the study is looking for
- Confirmed diagnosis of psoriatic disease, including psoriasis (any clinical variant) and/or psoriatic arthritis based on rheumatologic criteria.
- Receiving IL-23 inhibitor therapy (guselkumab or risankizumab).
- Treated within participating Costa Rican public health centers.
- Availability of sufficient clinical records to complete registry data (history, follow-up, labs).
- Age ≥12 years, any sex.
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Caja Costarricense del Seguro Social Coordinator of this site? Confirm its status | San José | Costa Rica | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.